Back to Awarded Treatment Trials
Awarded Trial: 02T-175
Grant ID
02T-175
Illness
Schizophrenia, prodromal stage
Primary Drug/Intervention
Glycine
Primary Dosage
0.8g/d/kg
Secondary Drug Intervention
N/A
Secondary Dosage
N/A
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Completed
Investigator
Woods
Sample Size
10
Duration of Study Period for Each Subject
8 weeks
Outcome Measurements
Scale of Prodromal Symptoms, YMS, Cognitive Battery
Results
Ten patients were enrolled and seven completed 8 weeks of the treatment. Three of seven patients met early remission criteria while on glycine. Ratings for positive symptoms showed the best improvement.
Publication
N/A
Link
N/A
PI Name
Scott Woods
Degree
MD
Center
School of Medicine
Institution
Yale University
Address
CMHC, 34 Park Street, Room B38
City or Town
New Haven
State or Province
CT
Zip or Postal Code
6519
Country
USA
Email Address
scott.woods@yale.edu